The world is anxiously awaiting effective treatments for COVID-19, which is ravaging most countries. Fortunately, some of the best minds in our public and private sectors are putting everything they have into developing effective vaccines, drugs, and tests that are so desperately needed. Because of the Bayh-Dole Act, which allows academic institutions and federal laboratories to effectively license their discoveries so they can make the leap from being laboratory concepts into useful products, these partnerships are proceeding at full speed. Unfortunately, some want to undo this model at the very time we need it the most.
Please join ITIF and the Bayh-Dole 40 Coalition for a video webinar delving into the critical role that partnerships between industry, academia, and federal labs will play in combating COVID-19, how these partnerships work, what risks they entail, why patents and licenses are so important in overcoming the risks inherent in developing drugs and vaccines, and how the Bayh-Dole Act enables the process for the benefit of people in the United States and around the world.
Speakers include:
Stephen Ezell, vice president, global innovation policy, Information Technology and Innovation Foundation
Joseph P. Allen, former president, National Technology Transfer Center
Wendy Commins Holman, CEO and founder, Ridgeback Biotherapeutics
Mark Rohrbaugh, special advisor for technology transfer, National Institutes of Health
Jon Soderstrom, managing director, university technology commercialization and faculty innovation, Yale University